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Poster Session I 79limited to skin, and limited chronic oral GVHD. Neither patient
developed EBV-PTLPD. CD31CD41 . 400/mm3 was achieved
by days1174 and1307, and each patient exhibited normalmitogen
responses to phytohemagglutinin and pokeweed by days 1275 and
1384. Vaccine responses to diphtheria and tetanus were noted in
the patient in whom titers were studied. There were no unexpected
toxicities related to the HSCT procedure, and both patients remain
alive greater than one year after HSCT with Lansky scores of 100.
Both are 100%donor chimerism byVNTR analysis, are transfusion
independent, had resolution of eczema, and have experienced com-
plete immune reconstitution. With these patients, we have demon-
strated that rapid hematopoietic engraftment and complete immune
reconstitution can be achieved with limited toxicity in patients with
WASwho receive a reduced intensity conditioning followed by a T-
and B-cell depleted haploidentical graft with specific T-cell add
back.212
SUCCESSFUL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR HIGH-RISK PAEDIATRIC ACUTE MYELOID LEUKAEMIA USING
CHEMOTHERAPY-ONLY CONDITIONING AND POST TRANSPLANT IM-
MUNOTHERAPY
Bonanomi, S.1, Connor, P.1,Webb, D.2, Ancliff, P.2, Persis, A.1, Rao, K.1,
McCloskey, D.3, Hemmatpour, S.3, Goulden, N.2, Veys, P.1. 1Great
Ormond Street Hospital for Children, London, United Kingdom; 2Great
Ormond Street Hospital for Children, London, United Kingdom; 3Royal
London Hospital, London, United Kingdom.
Objectives: The role of allogeneic stem cell transplantation
(SCT) in paediatric acute myeloid leukaemia (AML) remains con-
troversial. SCT has generally been advocated for poor risk disease
in first complete remission (CR), the majority of patients following
relapse, and as a last resort in refractory disease.Methods: Twelve
consecutive patients (median age 2.2 years) underwent SCT for
high risk AML between 2000 and 2006. Patient and graft character-
istics are shown in the table.
Conditioning regimen consisted of busulphan (Bu) 16 mg/Kg,
cyclophosphamide (Cy) 120 mg/Kg, melphalan (Mel) 140 mg/m2;
alemtuzumab 1 mg/Kg was added in the unrelated donor setting.
Immunotheraputic strategies were employed to maximise a graft-
versus-leukaemia (GVL) response escalating through a reducedPatient
Age at
SCT
FAB
type Antecedent Cytogenetics
Disease
phase Donor type
GVHD
prophylaxis
1 2.0 M6 3q del, trisomy 21 CR1 MMUD alemtuzumab
CSA MTX
2 2.2 M7 complex CR1 MUD alemtuzumab
CSA MTX
3 1.7 M6 complex resistant
disease
MUD alemtuzumab
CSA MTX
4 2.7 M5 normal partial remission
after relapse
MMUD alemtuzumab
CSA MTX
5 1.6 M5 t(1;7)(q23;p22)
t(7;9;11)
CR2 MMUD alemtuzumab
CSA MTX
6 2.1 M0 t(7;12) CR2 MMUD alemtuzumab
CSA MTX
7 3.6 M7 normal partial remission
after relapse
MSD CSA
8 1.4 M0 normal partial remission
after relapse
MUD alemtuzumab
CSA MTX
9 5.7 secondary
AML
monosomy
7 trisomy 8
CR1 MMUD alemtuzumab
CSA MTX
10 2.4 M7 MDS monosomy 7 transformed
to AML
MSD CSA MTX
11 5.4 M2 MDS monosomy 7 transformed
to AML
MUD alemtuzumab
CSA MTX
12 2.2 M5 JMML del 9q transformed
to AML
MUD alemtuzumab
CSA MTXdose of alemtuzumab, early taper of cyclosporine A (CSA), donor
lymphocyte infusion (DLI) and treatment with alpha-interferon
(a-IFN). Results: All patients engrafted. Three out 5 patients un-
dergoing matched unrelated donor SCT, who were not in remis-
sion, received a 50% reduced dose of alemtuzumab. In 8 children
CSA was stopped early\ 2 months (n 5 4) and\ 3 months (n 5
4). Six of 12 patients developed acute graft versus host disease
(aGVHD), 3 grade 2, 3 grade 1. Five patients have developed lim-
ited chronic GVHD (cGVHD). In one patient who developed re-
cipient T-cell chimerism 2 months after SCT despite reduced
dose alemtuzumab and early taper of CSA, a DLI of 106/Kg was ad-
ministered followed by a-IFN. He developed grade 1 aGVHD and
the donor T cell chimerism increased to 80% but he never achieved
full donor haemopoiesis and relapsed 17 months after SCT. In an-
other patient, who developed noGVHDdespite cessation of CSA at
day 32, a-IFN was administered: he developed grade 1 aGVHD
evolving to limited cGVHD and remains in remission at 9 months.
Ten of 12 (83%) patients are alive in CR at amedian of 33months
(range 9–80) from SCT. There was no transplant related mortality,
but two patients relapsed 3 and 17 months after SCT and subse-
quently died. Conclusion: This early promising data suggests
that the combination of Bu Cy Mel should be studied further as
a conditioning regimen in children with high risk AML. Given
the substantial risk of relapse, and in the absence of GVHD, this ap-
proach should be used as a platform for escalating immunothera-
peutic strategies with the endpoint of sustaining 100% donor
chimerism or achieving non severe GVHD to maximize the poten-
tial for a GVL effect.213
A NOVEL NON-MYELOABLATIVE CONDITIONING REGIMEN FOLLOWED
BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
PEDIATRIC PATIENTS WITH NON-MALIGNANT HEMATOLOGICAL DIS-
ORDERS
Hussein, A.A., Rihani, R., Rahman, F.A., Helalah, O.A., Taani, H.A.,
Nserat, T.A.L., Sarhan, M.M. King Hussein Cancer Center, Amman,
Jordan.
Purpose: To evaluate the efficacy of using a novel non-myeloa-
blative conditioning regimen followed by allogenic hematopoietic
stem cell transplantation (HSCT) for pediatric patients with non-
malignant hematological disorders.Paptients andMethods:Eight
patients less than 18 years of age with benign hematological diseases
and high risk features were transplanted fromHLA identical related
donors between October, 2004 and August, 2007. Six patients had
sever thalassemia major, one patient had sickle cell anemia and
one had pure red cell aplasia. Seven were males and one female.Me-
dian age was 12 years (5–16). All patients had high serum ferritin
(1500–6000 ng/mL). All patients had significant palpable hepato-
megaly (4–8 cm). Four patients had hepatitis C infection, 6 patients
had grade II-III hepatic fibrosis on liver biopsy and one patient had
uncontrolled Nephrotic syndrome.
All patients received non-ablative conditioning regimen con-
sisted of: Busulphan (2 mg/kg twice daily for two days), Fludarabine
(35 mg/m2/day for 5 days), Horse ATG (30 mg/kg/day for 5 days)
and total lymphoid irradiation (500 cGy onDay zero). Cyclosporine
and oral Mycophenolate Mofetil were used as Graft versus Host
Disease (GvHD) prophylaxis. Six patients received mobilized pe-
ripheral stem cells while two patients received G-CSF primed
bone marrow cells. Results: After a median follow up of 13 months
(2–36), all patients are alive and doing well with no blood transfu-
sion requirement. Mean CD34 graft dose was 4.4 106/kg. All pa-
tients showed primary neutrophil engraftment at a median of 19
days (12–24). Four patients have sustained full donor chimerim,
while 3 patients have stable mixed donor chimerism (52–94%),
only one patient had graft failure 10 months after HSCT and he
is now doing well with full donor chimerism 20 months following
second non-ablative transplantation.
No patient required ICU admission post transplantation. Four
patients developed acute veno-oclusive disorder within first 30
days after HSCT; all were salvaged with supportive treatment.
Three patients had Grade II-III acute GvHD. Two patients had
Grade I-II chronic GvHD. Two patients developed posterior
80 Poster Session Ireversible encephalopathy syndrome within 50 days post transplan-
tation, all of them showed complete clinical and radiological resolu-
tion. Conclusion: Non-myeloablative HSCT using this
conditioning regimen for high risk pediatric patients with benign
hematological disorders appears to be promising and worth further
study.214
PERICARDIAL EFFUSION (PEF) IS A MAJOR INDEPENDENT RISK FACTOR
ASSOCIATED WITH A SIGNIFICANT DECREASE IN SURVIVAL IN PEDIAT-
RIC STEM CELL TRANSPLANTATION (SCT) RECIPIENTS
Neier, M., Bhatia, M., Baldinger, L., Silver, E., Morris, E., van de
Ven, C., Kleinman, C., Jin, Z.Z., Cairo, M.S. Columbia University,
New York, NY.
Background: SCT is the treatment of choice for a variety of pe-
diatric conditions. Potential post SCT morbidities include cardiac
toxicity. Rhodes et al (BMT 2005) reported that PEF was seen in
4.4% of pediatric SCT recipients. Risk factors for the development
of PEF have been thought to include GVHD, infection and/or un-
derlying disease. There is a paucity of information regarding the eti-
ology, prognosis, treatment and outcome of PEF in a large cohort of
pediatric SCT recipients.Objectives: To assess the incidence, risk
factors, outcome of PEF and the impact of PEF on overall survival
(OS) in pediatric SCT recipients.Method: Echocardiograms were
performed at baseline prior to 200 SCT (4 were ineligible for re-
view) in 156 patients and when patients had symptoms and/or signs
of cardiac or pericardial disease post SCT. Probability of and time
to PEFwere analyzed by Kaplan-Meier method and risk of PEF and
deathwere determined bymultivariate analysis. Covariates included
age, gender, ethnicity, conditioning regimen, risk status (CIBMTR
criteria), conditioning regimen, donor source, CMV status,
GVHD, and HLA match. Results: The mean age was 8.15 years
(1/- 6.25 years) with 88 males and 68 females. 102 patients received
allogeneic transplants, 34 of them received more than 1 transplant.
116 of 156 recipients had malignant disease. 100 of 156 patients had
ablative conditioning. The incidence of PEF was 14.7%. A multi-
variate analysis shows that older age, poor risk and unrelated cord
blood donor recipients are significantly associated with a risk of de-
veloping PEF with hazard ratios of 1.125 (1.051–1.205), 3.508
(1.502–8.191), and 5.080 (1.141–22.625), respectively. OS was sig-
nificantly decreased in patients with PEF versus without PEF (haz-
ard ratio 5 4.84, 95% CI, 2.814–8.322, p\0.0001). Furthermore,
in a multivariate analysis, there was a significant decrease in OS as-
sociated with PEF, CMV status and poor risk status with hazard ra-
tios of 3.296 (1.73–6.26), 1.89 (1.08–3.30) and 1.93 (1.12–3.3),
respectively. Conclusion: These results demonstrate an almost
15% incidence of PEF in pediatric SCT recipients. Older, poor
risk and UCB donor recipients may be at higher risk of developing
PEF. PEFwas associatedwith themost significant impact on overall
mortality independent of other risk factors. Improved prevention
and therapeutic strategies for development of PEF in post allo
SCT recipients may potentially reduce mortality in the future.215
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN WISKOTT
ALDRICH SYNDROME (WAS): A SINGLE CENTER EXPERIENCE IN 25 PA-
TIENTS
Bonfim, C.M.S., Koliski, A., Bitencourt, M.A., Quiroga, M.,
Setubal, D.C., Funke, V., Ruiz, J., Medeiros, L., Oliveira, M.,
Coutinho, E., Zanis Neto, J., de Medeiros, C.R., Pasquini, R. Federal
University of Parana, Curitiba, PR, Brazil.
WAS is a rare X-linked disease characterized by eczema, micro-
thrombocytopenia, recurrent infections, autoimmune complica-
tions and malignancies. The gene responsible for WAS has been
identified and termed WASP. Without a successful HSCT, the
prognosis of classical WAS with a complete absence of WASP ex-
pression is poor. In this report we analyze the outcome of 25 pts
transplanted in a single center in a developing country.Material and Methods: Period: 04/92–02/07; age:1–14 ys-
old(M:2 ys). Eight pts received bone marrow(BM) from HLA
matched (5 pts) or mismatched family donors(3 pts). 17 pts received
an unrelated cord blood(URD CB). Preparatory regimen: Busul-
fan(BU)16 mg/kg1Cyclophosphamide 120–200 mg/kg in 24 pts
or BU8 mg/kg 1 Fludarabine 125 mg/m2:1 pt. ATG(rabbit) was
added to patients transplanted from unrelated donors or mis-
matched family donors. GVHD prophylaxis: Cyclosporine(Csa)1
MTX:16 pts; Csa 1 steroids:8 pts and Csa 1 MMF:1 pt. After
2005, all pts submitted to an URD CB transplantation, received
Csa1MTX as GVHD prophylaxis if the TNC infused was . 3.0
 10*7/kg. Results: 21 pts(84%) are alive between 100 – 4745
days (M:790 d) after HSCT. All pts survived more than 28 days
and were evaluable for engraftment. Primary graft failure (PGF) oc-
curred in 2 pts (both URD CB 4/6) and one pt was submitted to
a successful 2nd transplant. Most pts tolerated the procedure very
well. See table below for transplant related complications.23/25
pts were analyzed for chimerism (VNTR). 13 pts had a complete
chimerism. Ten pts were mixed chimeras immediately after
HSCT and, later on, 3 pts became full chimeras. Four pts had auto-
immune complications after transplant: 3 pts had idiopathic throm-
bocytopenic purpura(ITP) and one pt had severe auto immune
hemolytic anemia (AIHA). Frequent viral infections (CMV, EBV,
adenovirus) occurred in pts submitted to URD CB transplants. 2/
21 surviving pts have permanent sequels from neurological viral in-
fections. Conclusions: The excellent survival in this group of pts
confirms the efficacy of HSCT in this disease. Pts receiving
HSCT from 4/6 URDCB have a lower survival. Reactivation of vi-
ral infections were frequent complications in our pts and should be
monitored closely.
Post-transplant complications
URD CB BM from BM fromCompatibility:
6/6 or 5/6
N 5 11 ptsURD CB
Compatibility:
4/6 N 5 6 ptsmatched family
donors
N 5 5 ptsmismatched
family donors
N 5 3 ptsGraft failure 0 2 0 0Acute GVHD
grade III-IV3/11 1/4 0 0Chronic GVHD
extensive2/11 1/4 0 0Mixed chimeras 3 pts 2 pts 2 pts 0Auto immune
complications0 2 pts (ITP
and AIHA)1 pt (ITP) 1 pt (ITP)Overall Survival 91% 66% 80% 100%Causes of death 1 pt: D 1
1825:
bronchopneumonia
1 respiratory
failure2 pts: D 1 34 :
PGF1 fungal
infection and
D 1 132 :
C-GVHD 1
bacterial sepsis1 pt:D 1 62:
CMV pneumonia
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IRON OVERLOAD IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) PATIENTS
Barry, E.V.1,2, Chirnomas, D.1,2, Barry, K.2, Duncan, C.N.1,2,
Lehmann, L.1,2. 1Dana-Farber Cancer Institute, Boston, MA; 2Chil-
dren’s Hospital Boston, Boston, MA.
Background: Iron can be a highly toxic molecule to cells and tis-
sues when it interacts with oxygen and generates free radicals. Free
iron, ferritin and transferrin saturation have been shown to increase
acutely in HSCT patients, and high ferritin levels can persist for
years following HSCT. The prevalence of iron overload has not
been defined in this population, and currently, no management
guidelines exist. We describe a group of pediatric HSCT patients
who were diagnosed with iron overload after developing liver func-
tion abnormalities and/or hyper-ferritinemia. Methods: We per-
formed a detailed retrospective review of patients identified as
having iron overload following allogeneic HSCT performed be-
tween 2001–2007. We included a subset of patients with known
